Aurinia’s lead product, Lupkynis® (voclosporin), is an oral medication approved for the treatment

Aurinia’s lead product, Lupkynis® (voclosporin), is an oral medication approved for the treatment of adult patients with active lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE). Lupkynis® is designed to reduce inflammation and improve renal function in patients with this challenging condition.The development of Lupkynis® has been supported by extensive clinical trials, demonstrating its efficacy and safety in treating lupus nephritis. In addition to lupus nephritis, Aurinia is exploring therapies for other autoimmune and inflammatory diseases. The company’s pipeline includes programs targeting conditions such as dry eye disease and additional autoimmune disorders. Aurinia Pharmaceuticals is committed to advancing its pipeline through rigorous research and development:The company employs innovative approaches and technologies to drive drug discovery and development, focusing on novel mechanisms of action and improved treatment outcomes. Clinical Trials: Aurinia conducts comprehensive clinical trials to evaluate the safety and efficacy of its product candidates, ensuring that its therapies meet high standards of clinical and regulatory excellence.Scientific Collaboration: Aurinia collaborates with leading research institutions and industry partners to enhance its R&D efforts and accelerate the development of its therapies.2024: Successfully completed infill drilling at Parks/Salyer and Cactus West, rezoned MainSpring to Industrial Use, released Pre Feasibility Study on Cactus, and confirmed near surface mineralization at MainSpring.